Literature DB >> 22797065

Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination.

M Krajewska1, A M Heijink, Y J W M Bisselink, R I Seinstra, H H W Silljé, E G E de Vries, M A T M van Vugt.   

Abstract

In response to DNA breaks, the 'DNA damage response' provokes a cell cycle arrest to facilitate DNA repair. Recent findings have indicated that cells can respond to DNA damage throughout the cell cycle, except during mitosis. Specifically, various mitotic kinases, including Cdk1, Aurora A and Plk1, were shown to inactivate key DNA damage checkpoint proteins when cells enter mitosis. Aberrant activation of mitotic kinases during interphase could therefore modulate cellular responses to DNA damage. In this study, our aim was to determine how aberrant activation of Cdk1 affects the cellular responses to DNA damage. We used Wee1 inhibition, using MK-1775, to force Cdk1 activation, which did not cause cytotoxicity in non-transformed cells. Instead, it accelerated mitotic entry and caused radio sensitization in p53-defective cancer cells, but not in p53-proficient cancer cells. Interestingly, we showed that Wee1 inhibition leads to elevation of Cdk1 activity in interphase cells. When we subsequently analyzed DNA damage responses in cells with forced Cdk1 activation, we observed a marked reduction of 53BP1 at sites of DNA damage along with an increase in γ-H2AX staining after irradiation, indicative of defective DNA repair. Indeed, when DNA repair was analyzed using in vivo endonuclease-induced homologous recombination (HR) assays, compromised DNA repair after Wee1 inhibition was confirmed. This defect in HR was accompanied by increased phosphorylation of BRCA2 at the Cdk1 phosphorylation site S3291. Taken together, our results indicate that Wee1 inhibition leads to forced Cdk1 activation in interphase cells, which interferes with normal DNA damage responses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22797065     DOI: 10.1038/onc.2012.296

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  64 in total

1.  Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors.

Authors:  Shrikanta Chattopadhyay; Alison L Stewart; Siddhartha Mukherjee; Cherrie Huang; Kimberly A Hartwell; Peter G Miller; Radhika Subramanian; Leigh C Carmody; Rushdia Z Yusuf; David B Sykes; Joshiawa Paulk; Amedeo Vetere; Sonia Vallet; Loredana Santo; Diana D Cirstea; Teru Hideshima; Vlado Dančík; Max M Majireck; Mahmud M Hussain; Shambhavi Singh; Ryan Quiroz; Jonathan Iaconelli; Rakesh Karmacharya; Nicola J Tolliday; Paul A Clemons; Malcolm A S Moore; Andrew M Stern; Alykhan F Shamji; Benjamin L Ebert; Todd R Golub; Noopur S Raje; David T Scadden; Stuart L Schreiber
Journal:  Cell Rep       Date:  2015-02-05       Impact factor: 9.423

Review 2.  The control of DNA repair by the cell cycle.

Authors:  Nicole Hustedt; Daniel Durocher
Journal:  Nat Cell Biol       Date:  2016-12-23       Impact factor: 28.824

3.  The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.

Authors:  Leslie A Parsels; Joshua D Parsels; Daria M Tanska; Jonathan Maybaum; Theodore S Lawrence; Meredith A Morgan
Journal:  Cell Cycle       Date:  2018-07-18       Impact factor: 4.534

4.  Multiple Defects Sensitize p53-Deficient Head and Neck Cancer Cells to the WEE1 Kinase Inhibition.

Authors:  Ahmed Diab; Michael Kao; Keffy Kehrli; Hee Yeon Kim; Julia Sidorova; Eduardo Mendez
Journal:  Mol Cancer Res       Date:  2019-01-24       Impact factor: 5.852

Review 5.  Emerging Treatment Paradigms in Radiation Oncology.

Authors:  Quynh-Thu Le; Hiroki Shirato; Amato J Giaccia; Albert C Koong
Journal:  Clin Cancer Res       Date:  2015-05-19       Impact factor: 12.531

6.  Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.

Authors:  Tamara B Garcia; Susan P Fosmire; Christopher C Porter
Journal:  Leuk Res       Date:  2017-11-11       Impact factor: 3.156

Review 7.  Wee1 kinase as a target for cancer therapy.

Authors:  Khanh Do; James H Doroshow; Shivaani Kummar
Journal:  Cell Cycle       Date:  2013-08-26       Impact factor: 4.534

8.  Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.

Authors:  David Karnak; Carl G Engelke; Leslie A Parsels; Tasneem Kausar; Dongping Wei; Jordan R Robertson; Katherine B Marsh; Mary A Davis; Lili Zhao; Jonathan Maybaum; Theodore S Lawrence; Meredith A Morgan
Journal:  Clin Cancer Res       Date:  2014-08-12       Impact factor: 12.531

Review 9.  Improving the efficacy of chemoradiation with targeted agents.

Authors:  Meredith A Morgan; Leslie A Parsels; Jonathan Maybaum; Theodore S Lawrence
Journal:  Cancer Discov       Date:  2014-02-18       Impact factor: 39.397

Review 10.  Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer.

Authors:  Shih-Hung Yang; Ting-Chun Kuo; Hsu Wu; Jhe-Cyuan Guo; Chiun Hsu; Chih-Hung Hsu; Yu-Wen Tien; Kun-Huei Yeh; Ann-Lii Cheng; Sung-Hsin Kuo
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.